Refractory anemia with ringed sideroblasts (RARS)

2003-11-01   Antonio Cuneo , Gianluigi Castoldi 

1.Hematology Section, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca 203, Ferrara, Italy

Clinics and Pathology

Phenotype stem cell origin

RARS is a clonal disorder originating from a totipotent stem cell or from a multipotent myeloid progenitor cell, characterized by ineffective hemopoiesis and diserythropoiesis.

Epidemiology

There are few data on the epidemiology of RARS, which may account for 5-15% of all MDS cases. MDS is predominantly diagnosed in the elderly population. The global incidence of all MDS was comprised between 3,5 and 12,6 new cases / year / per 100,000 in some studies. The incidence may rise from 0,5 MDS cases per year in the 40 years age-group to 89 cases per year in the >80 age-group.

Clinics

RARS usually presents with hypercellular bone marrow (BM) and anemia. There may be leukopenia and/or and thrombocytopenia, but these features do not represent a diagnostic requirement.
According to the WHO classification RARS shows anemia, no blasts in the peripheral blood, isolated erythroid dysplasia with <5% blasts and >15% ringed sideroblasts in the BM. RCMD-RS shows cytopenias (bicytopenia or pancytopenia) in the peripheral blood plus dysplasia in more than 10% of the cells in 2 or more myeloid lineages and no Auer rods.

Cytology

Criteria for the recognition of dysplastic features of BM cells were published by the FAB group. Typically, more than 15% of the erythroid cells are ringed sideroblasts showing iron laden mitochondria around the nucleus. These cells appear as erythroblast with Prussian Blue-positive granules which form an arc extending around at least 30% of the nucleus. There is evidence that mutations occurring in the mitochondrial DNA may have a role in generating deranged mitochondrial iron metabolism with consequent accumulation of the of the ferric form (Fe3+) in the matrix.

Pathology

The bone biopsy may be useful in some cases of MDS with BM fibrosis and allows for the demonstration of the so called "abnormal localization of immature precursors" (ALIP) which may represent a prognostic factor.

Treatment

Treatment of this condition is largely supportive, including blood transfusion in patients with symptomatic anemia. Anemic patients with low serum erythropoietin (EPO) levels may benefit of the administration of rHu-EPO.

Evolution

This is a preleukemic condition, carrying a 10-20% probability of evolving into leukemia. The probability of RARS to transform into AML may be lower when excluding RCMD, but prospective studies are lacking. In a study 25% of the patient developed acute myeloid leukemia (AML) in approximately 10 years.

Prognosis

Median survival of RARS may fall in the 40-50 month range.
Chromosomal abnormalities have independent prognostic significance and are to be included in risk assessment at diagnosis. Favourable cytogenetic features are normal karyotype, 5q- syndrome or 20q- isolated; unfavourable features are complex karyotype (i.e. 3 or more clonal anomalies) and abnormalities of chromosome 7q; other abnormalities identify patients in the intermediate cytogenetic-risk group.

Bibliography

Pubmed IDLast YearTitleAuthors
116944002001Myelodysplastic syndromes: recent advances.Alessandrino EP et al
69529201982Proposals for the classification of the myelodysplastic syndromes.Bennett JM et al
87226831996Cytogenetics of myelodysplastic syndromes.Fenaux P et al
23106961990Two types of acquired idiopathic sideroblastic anaemia (AISA)Gattermann N et al
23198061990Prognostic factors of myelodysplastic syndromes--a simplified 3-D scoring system.Goasguen JE et al
78137081994Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients.Maschek H et al
117536032001Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype.Rigolin GM et al
84642271993Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan.Toyama K et al
122391372002The World Health Organization (WHO) classification of the myeloid neoplasms.Vardiman JW et al
82312321993De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features?Wattel E et al

Summary

Note

This disorder is part of the heterogeneous category of myelodysplastic syndrome (MDS). According to the FAB classification of MDS, RARS includes those patients with refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS), the latter category having been recognised as a distinct entity by the WHO classification (vide infra).
In this card, the FAB classification will be used, because the majority of available data on cytogenetic anomalies was derived from studies published before WHO classification.

Citation

Antonio Cuneo ; Gianluigi Castoldi

Refractory anemia with ringed sideroblasts (RARS)

Atlas Genet Cytogenet Oncol Haematol. 2003-11-01

Online version: http://atlasgeneticsoncology.org/haematological/1106/refractory-anemia-with-ringed-sideroblasts-(rars)

External Links